News
EC clears AstraZeneca’s acquisition of Alexion
The European Commission (EC) has cleared AstraZeneca’s proposed acquisition of rare disease specialist Alexion, initially announced in December 2020.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
The European Commission (EC) has cleared AstraZeneca’s proposed acquisition of rare disease specialist Alexion, initially announced in December 2020.